Head_Type,Head_Entity,Relation,Tail_Type,Tail_Entity,Description
Disease,Alzheimer's disease,has_biomarker,Biomarker,Tau,阿尔茨海默病的生物标志物包括Tau
Clinical_Test,Erlangen Score,predicts,Clinical_Stage,progression to dementia,Erlangen评分用于预测进展为痴呆的临床阶段
Clinical_Test,Erlangen Score,classifies,Clinical_Stage,neurochemically probable AD,Erlangen评分用于分类神经化学可能的AD阶段
Clinical_Test,Mini Mental State Examination,evaluates,Clinical_Manifestation,cognitive function,简易精神状态检查用于评估认知功能
Clinical_Test,Erlangen Score,classifies,Disease,neurochemically improbable AD,Erlangen评分将患者分类为神经化学上不太可能的AD
Disease,Alzheimer's disease,has_clinical_stage,Clinical_Stage,MCI-AD,MCI-AD是阿尔茨海默病的临床分期
Biomarker,CSF Aβ42/40,correlates_with,Clinical_Stage,MCI-Stable,CSF Aβ42/40与MCI-Stable阶段相关
Biomarker,CSF Aβ42/40,correlates_with,Clinical_Stage,neurochemically probable AD,CSF Aβ42/40与神经化学可能的AD阶段相关
Biomarker,CSF Tau,correlates_with,Clinical_Stage,neurochemically probable AD,CSF Tau与神经化学可能的AD阶段相关
Disease,MCI,progresses_to,Disease,Alzheimer's disease,轻度认知障碍可能进展为阿尔茨海默病痴呆
Disease,Alzheimer's disease,has_pathological_change,Pathological_Change,amyloidosis,阿尔茨海默病的病理改变包括淀粉样变性
Imaging_Method,SPECT,detects,Pathological_Change,brain function,SPECT可检测脑功能
Disease,Alzheimer's disease,has_clinical_stage,Clinical_Stage,ADD,ADD是阿尔茨海默病的临床分期
Clinical_Test,Erlangen Score,classifies,Clinical_Stage,neurochemically improbable AD,Erlangen评分用于分类神经化学不可能的AD阶段
Clinical_Test,Erlangen Score,predicts,Disease,Alzheimer's disease,Erlangen评分可预测阿尔茨海默病痴呆的进展概率
Risk_Factor,age,increases_risk_of,Disease,Alzheimer's disease,年龄是阿尔茨海默病的风险因素
Clinical_Test,Erlangen Score,interprets,Biomarker,CSF AD biomarkers,Erlangen评分有助于解释脑脊液生物标志物的复杂模式
Biomarker,CSF pTau181,correlates_with,Clinical_Stage,slow progressors,CSF pTau181与缓慢进展者相关
Research_Method,Linear Regression,models,Biomarker,CSF biomarkers,线性回归用于建模CSF生物标志物的浓度
Clinical_Test,Erlangen Score,classifies,Disease,Alzheimer's disease,Erlangen评分将阿尔茨海默病分为不同神经化学类别
Clinical_Stage,mild cognitive impairment,progresses_to,Clinical_Stage,Alzheimer's disease dementia,轻度认知障碍可能进展为阿尔茨海默病痴呆
Research_Method,Extended Cox Model,estimates,Risk_Factor,progression to dementia,扩展Cox模型用于估计进展为痴呆的风险
Biomarker,CSF Aβ1-42,correlates_with,Clinical_Stage,neurochemically probable AD,CSF Aβ1-42与神经化学可能的AD阶段相关
Disease,Alzheimer's disease,has_biomarker,Biomarker,CSF Aβ42/40,阿尔茨海默病的生物标志物包括CSF Aβ42/40
Clinical_Test,Erlangen Score,defines,Border_Zone,border zone results,Erlangen评分定义了边界区结果
Biomarker,CSF pTau181,correlates_with,Clinical_Stage,neurochemically probable AD,CSF pTau181与神经化学可能的AD阶段相关
Research_Method,Logistic Regression,models,Probability,progression to ADD,逻辑回归用于建模进展为ADD的概率
Disease,Alzheimer's disease,has_biomarker,Biomarker,amyloid beta (Aβ) 1-42,阿尔茨海默病的生物标志物包括Aβ1-42
Disease,Alzheimer's disease,has_biomarker,Biomarker,Aβ42/40,阿尔茨海默病的生物标志物包括Aβ42/40
Disease,Alzheimer's disease,has_biomarker,Biomarker,CSF Aβ1-42,阿尔茨海默病的生物标志物包括CSF Aβ1-42
Clinical_Test,Erlangen Score,classifies,Disease,neurochemically probable AD,Erlangen评分将患者分类为神经化学上很可能的AD
Clinical_Test,Erlangen Score,classifies,Disease,neurochemically normal,Erlangen评分将患者分类为神经化学正常
Risk_Factor,female gender,increases_risk_of,Disease,Alzheimer's disease,女性性别是阿尔茨海默病的风险因素
Biomarker,CSF Tau,correlates_with,Clinical_Stage,MCI-AD,CSF Tau与MCI-AD阶段相关
Disease,Alzheimer's disease,has_biomarker,Biomarker,CSF Tau,阿尔茨海默病的生物标志物包括CSF Tau
Imaging_Method,MRI,detects,Pathological_Change,brain atrophy,MRI可检测脑萎缩
Clinical_Test,MMSE,evaluates,Clinical_Manifestation,cognitive function,简易精神状态检查用于评估认知功能
Biomarker,CSF Aβ1-42,correlates_with,Clinical_Stage,fast progressors,CSF Aβ1-42与快速进展者相关
Disease,Alzheimer's disease,has_pathological_change,Pathological_Change,neurodegeneration,阿尔茨海默病的病理改变包括神经退行性变
Disease,Alzheimer's disease,has_biomarker,Biomarker,CSF pTau181,阿尔茨海默病的生物标志物包括CSF pTau181
Biomarker,CSF Aβ1-42,correlates_with,Clinical_Stage,MCI-Stable,CSF Aβ1-42与MCI-Stable阶段相关
Disease,Alzheimer's disease,has_biomarker,Biomarker,pTau181,阿尔茨海默病的生物标志物包括pTau181
Disease,Alzheimer's disease,has_risk_factor,Risk_Factor,APOE ε4,APOE ε4是阿尔茨海默病的风险因素
Biomarker,CSF Aβ42/40,correlates_with,Clinical_Stage,fast progressors,CSF Aβ42/40与快速进展者相关
Disease,Alzheimer's disease,has_pathological_change,Pathological_Change,amyloid pathway alteration,阿尔茨海默病的病理改变包括淀粉样蛋白通路改变
Clinical_Test,Erlangen Score,assesses,Biomarker,CSF biomarkers,Erlangen评分用于评估脑脊液生物标志物
Clinical_Test,Erlangen Score,predicts,Disease,Alzheimer's disease dementia,Erlangen评分可用于预测从MCI进展为阿尔茨海默病痴呆的风险
Biomarker,CSF Tau,correlates_with,Clinical_Stage,slow progressors,CSF Tau与缓慢进展者相关
Gene,APOE ε4,increases_risk_of,Disease,Alzheimer's disease,APOE ε4基因增加阿尔茨海默病的风险
Disease,Alzheimer's disease,has_biomarker,Biomarker,CSF AD biomarkers,阿尔茨海默病的脑脊液生物标志物有助于诊断
Clinical_Test,Erlangen Score,classifies,Clinical_Stage,neurochemically possible AD,Erlangen评分用于分类神经化学可能的AD阶段
Clinical_Test,CSF biomarkers,indicates,Disease,Alzheimer's disease,脑脊液生物标志物可用于指示阿尔茨海默病
Research_Method,Extended Cox Model,analyzes,Clinical_Stage,progression from MCI to ADD,扩展Cox模型用于分析从MCI到ADD的进展
Biomarker,CSF pTau181,correlates_with,Clinical_Stage,MCI-AD,CSF pTau181与MCI-AD阶段相关
Clinical_Test,Erlangen Score,classifies,Disease,neurochemically possible AD,Erlangen评分将患者分类为神经化学上可能的AD
